Patient foundation accuses rare disease company Taysha of violating licensing agreement
16 Nov 2023
License out/in
A patient group this summer accused Taysha Gene Therapies of breaching a contract to develop a therapy for an ultra-rare condition, another sign of deep tensions between the company and family foundations.
In July, Hannah’s Hope Fund claimed that Taysha breached a licensing agreement that called for the company to develop a therapy for giant axonal neuropathy, an ultra-rare condition that renders patients quadriplegic and is followed by early death, according to an SEC filing on Tuesday.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.